Abstract 748P
Background
Advanced ARID1A-mutated ovarian clear cell carcinoma (OCCC) is a rare disease with poor prognosis that shows limited response to chemotherapy. These patients have not been adequately represented in clinical trials. Oral, next-generation, dual EZH2/EZH1 inhibitor tulmimetostat is in Phase II evaluation in multiple disease cohorts (NCT04104776); we report updated efficacy, safety, and pharmacodynamic findings from the OCCC cohort including new dose optimization arms.
Methods
Phase II Stage 1 evaluated tulmimetostat 350 mg once daily (QD). In Stage 2a (initiation of dose optimization), patients (n=20) with ARID1A-mutated OCCC were randomized 1:1 to either 300 mg or 200 mg QD arms. Observation of ≥2 confirmed complete/partial responses (CR/PR) in each arm in Stage 2a is sufficient per protocol to fully open Stage 2b (plus n=20). Primary endpoint is objective response rate (CR/PR); secondary endpoints include safety.
Results
As of February 18, 2024, 10, 10 and 14 patients with OCCC were enrolled into the 200 mg, 300 mg and 350 mg arms, respectively; 70%, 40% and 57% of patients had received ≥3 prior treatment lines, respectively. Confirmed responses in the OCCC cohort (table) met the criteria for Stage 2b expansion. The safety profile across dose arms was consistent with known class effects. Grade ≥3-related AEs were primarily hematologic (table). Similar pharmacodynamic effects were observed across all three doses as assessed by changes in gene expression. Table: 748P
Response and safety summary in the OCCC cohort ∗
Dose, mg | 200 | 300 | 350 | |
Efficacy evaluable OCCC, N | 10 | 10 | 14 | |
Best confirmed response, † n | CR PR SD | 0 3 5 | 0 2 5 | 0 1 7 |
PD Discontinued without response assessment | 1 1 | 3 0 | 6 0 | |
Safety evaluable, N | 10 | 10 | 14 | |
Any TEAEs, n (%) | 10 (100) | 10 (100) | 14 (100) | |
Any grade-related TEAEs, n (%) | 10 (100) | 10 (100) | 14 (100) | |
Grade ≥3-related TEAEs (≥10% in any OCCC arm), n (%) | Thrombocytopenia | 1 (10) | 2 (20) | 4 (28.6) |
Anemia | 2 (20) | 0 | 7 (50) | |
Neutropenia | 0 | 0 | 2 (14.3) | |
Diarrhea | 0 | 2 (20) | 0 | |
Vomiting | 1 (10) | 0 | 0 | |
Fatigue | 1 (10) | 0 | 0 |
∗Data cutoff 18-Feb-24.
†RECIST 1.1. CR, complete response; OCCC, ovarian clear cell carcinoma; PD, progressive disease; PR, partial response; SD, stable disease.
Conclusions
This ongoing Phase II data in patients with heavily pretreated ARID1A-mutated OCCC show signs of antitumor activity across dose levels. Response requirements to open Stage 2b have been met in this fast enrolling disease cohort. The safety profile across doses is consistent with EZH2 inhibition. These data support continued investigation of tulmimetostat.
Clinical trial identification
NCT04104776.
Editorial acknowledgement
Medical writing and editorial support for the development of this abstract was provided by Zaavan Baildon of Syneos Health, UK, funded by MorphoSys AG.
Legal entity responsible for the study
Constellation Pharmaceuticals, Inc.
Funding
Constellation Pharmaceuticals, Inc.
Disclosure
A. Oaknin: Financial Interests, Personal, Advisory Board, membership: Agenus, AstraZeneca, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals, Daiichi Sankyo, Debiopharm International, Eisai, Exelisis, F. Hoffmann-La Roche, Genmab, GSK, ImmunoGen, Itheos, MSD, Mersana Therapeutics, Myriad Genetics, Novocure, OncoXerna Therapeutics, Inc., PharmaMar, Regeneron, Shattuck Labs, Seagen/Pfizer, SutroBiopharma, Zentalis; Financial Interests, Personal, Other, Travel/accomodation: AstraZeneca, PharmaMar, Roche. C. Drescher: Financial Interests, Personal, Leadership Role: Rivkin Center, Powell-Drescher Ovarian Cancer Research Foundation, Swedish Cancer Institute; Financial Interests, Personal, Research Funding: NCI, Canary Foundation. K. Banda: Financial Interests, Personal, Other, Honoraria: GSK, ImmunoGen; Financial Interests, Institutional, Research Funding: Lilly, MorphoSys, Regeneron, Pfizer, Kineta. L. Duska: Financial Interests, Personal, Advisory Role: Regeneron, Inovio Pharmaceuticals; Financial Interests, Institutional, Advisory Role: Merck, Ellipses Pharma, GSK, Millenium, Bristol Myers Squibb, Aeterna Zentaris, Novartis, AbbVie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Syndax, Pfizer, Genentech/Roche, Morab, Morphotek, Ludwig Institute for Cancer Research; Financial Interests, Personal, Other, Patents, Royalties, Other Intellectual Property: UpToDate, Editor, British Journal of Obstetrics and Gynaecology. V. Ribrag: Financial Interests, Personal, Speaker’s Bureau: AbbVie, BeiGene, Ipsen; Financial Interests, Personal, Research Funding: Astex, GSK; Financial Interests, Personal, Member of Board of Directors: AstraZeneca, Lilly; Financial Interests, Personal, Full or part-time Employment: Pegascy. A. Tewari: Financial Interests, Personal, Advisory Role: Best Doctors, Inc; Financial Interests, Personal, Stocks or ownership: Moderna Therapeutics, Teladoc, B.A.I. Biosciences; Financial Interests, Personal, Other, Honoraria: UroToday. N.J. Lakhani: Financial Interests, Institutional, Research Funding: Alexo Therapeutics, Ascentage Pharma, BeiGene, Constellation Pharmaceuticals, Forty Seven, Loxo, Macrogenics, Merck, Pfizer, Regeneron, Apexian Pharmaceuticals, Coordination Therapeutics, Symphogen, CytomX Therapeutics, InhibRx, Incyte, Jounce Therapeutics, Livzon, Norhern Biologics, Tesaro, Innovent Biologics, LAM Therapeutics, Ikena Oncology, Celgene, Shattuck Labs, Alpine Immune Sciences, Genmab, Odonate Therapeutics, Mersana, Seagen, Astellas Pharma, Celgene, Helsinn Therapeutics, Ikena Oncology, Lilly, Sapience Therapeutics, Epizyme, Gilead Sciences, GSK, Tizona Therapeutics, Inc., Servier, Alkermes, KSQ Therapeutics, Repare Therapeutics, Biosplice, SK Life Sciences, Janssen, Arcus Ventures, Artios, BioNTech, Mural Oncology. L. Eberst: Financial Interests, Personal, Advisory Role: MSD/AstraZeneca, GSK; Financial Interests, Personal, Other, Travel, Accommodations, Expenses.: AstraZeneca. R..D. Harvey: Financial Interests, Personal, Advisory Role: Janssen Oncology, Ribometrix, EMD Serono; Financial Interests, Institutional, Research Funding: Meryx Pharmaceuticals, Janssen Research & Development; Financial Interests, Personal, Research Funding: MorphoSys. L.M. Manso Sanchez: Financial Interests, Personal, Advisory Role: Roche/Genentech, AstraZeneca, Novartis, Pfizer, Tesaro, Eisai, Lilly, Clovis Oncology, Pierre Fabre, GSK; Financial Interests, Personal, Speaker’s Bureau: Roche/Genentech, Novartis, Pfizer, AstraZeneca, Lilly; Financial Interests, Personal, Research Funding: Tesaro; Financial Interests, Personal, Other, Travel, Accommodations, Expenses.: Roche/Genentech, Novartis, Tesaro, MSD Oncology, GSK. D. Lorusso: Financial Interests, Personal, Advisory Board, Participation in advisory boards: AstraZeneca, Clovis Oncology, GSK, MSD; Financial Interests, Personal, Advisory Board, also invited member: Corcept, Genmab, ImmunoGen, Oncoinvest, Seagen, Sutro; Financial Interests, Personal, Advisory Board: Novocure; Financial Interests, Personal, Other, Consultancy: MSD, Novartis; Financial Interests, Personal, Invited Speaker, for advisory board: AstraZeneca, Clovis Oncology, Daiichi Sankyo, Genmab, GSK, ImmunoGen, MSD, Novocure, Seagen; Financial Interests, Institutional, Funding, Clinical trial/contracted research: AstraZeneca, Clovis Oncology; Financial Interests, Institutional, Funding, grant for founding academic trials: Clovis Oncology, Pharmaand, GSK, MSD; Financial Interests, Institutional, Funding, Clinical trials/contracted research: Genmab, GSK, ImmunoGen, Incyte, MSD, Novartis, Roche, Seagen, Alkermes, Corcept; Non-Financial Interests, Personal, Principal Investigator, PI of several trials. No personal compensation received: AstraZeneca, Clovis Oncology, Genmab, GSK, Incyte, MSD; Non-Financial Interests, Personal, Principal Investigator, PI of clinical trial. No personal compensation received: ImmunoGen, Novartis, Roche, Seagen, Corcept; Non-Financial Interests, Personal, Principal Investigator, PI of clinical trials. No personal compensation received: PharmaMar; Non-Financial Interests, Personal, Member of Board of Directors: GCIG; Non-Financial Interests, Personal, Member, President Elect: MITO; Non-Financial Interests, Personal, Member, Coordinating PI of several trials: ENGOT; Other, Personal, Other, Grants for travelling: AstraZeneca, Menarini, GSK, MSD. H.S. Walter: Financial Interests, Personal, Other, Honoraria: BeiGene, Genmab, Loxo, AstraZeneca; Financial Interests, Personal, Advisory Role: Genmab, BeiGene, Loxo; Financial Interests, Personal, Research Funding: Gilead Sciences, Pfizer. D.G. Illescas: Financial Interests, Personal, Speaker’s Bureau: GSK, AstraZeneca; Financial Interests, Personal, Other, Travel and accommodation fees: GSK, MSD; Financial Interests, Personal, Speaker’s Bureau, Travel and accommodation fees: AstraZeneca. E. Pons-Tostivint: Financial Interests, Personal, Advisory Role: AstraZeneca, Sanofi Pasteur, Takeda; Financial Interests, Personal, Other, Travel, accommodations, expenses: AstraZeneca, Takeda, Pfizer, Sanofi. A.G. Thakur, L. Kann, A. Reddy, N. Faulhaber: Financial Interests, Personal, Full or part-time Employment: MorphoSys. A. González-Martín: Financial Interests, Personal, Advisory Role: Roche, Tesaro/GSK, Clovis Oncology, AstraZeneca, MSD, Genmab, ImmunoGen, Oncoinvent, Pfizer/EMD Serono, Amgen, Mersana, SOTIO, Sutro Biopharma, Macrogenics, Novartis, Alkermes, Hedera Dx, Novocure, Seagen, Takeda, Kartos Therapeutics, Tubulis GmbH; Financial Interests, Personal, Speaker’s Bureau: Roche, AstraZeneca, Tesaro/GSK, PharmaMar, Clovis Oncology, MSD Oncology; Financial Interests, Personal, Other, Travel/ Accommodations, Expenses.: Roche, AstraZeneca, PharmaMar, Tesaro/GSK, MSD Oncology; Financial Interests, Institutional, Research Funding: Roche, Tesaro/GSK. All other authors have declared no conflicts of interest.
Resources from the same session
661P - Safety and activity of CY-101 in patients with advanced solid tumors: The phase I/IIa CICILIA trial
Presenter: Barend Sikkema
Session: Poster session 01
662P - A phase I study evaluating IMM2520 (CD47/PD-L1 bispecific molecule) in pts with advanced solid tumor
Presenter: Yuping Sun
Session: Poster session 01
663P - First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumors
Presenter: Muhammad Khattak
Session: Poster session 01
664P - Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)
Presenter: Maria Julia Lostes Bardaji
Session: Poster session 01
665P - Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Thomas Marron
Session: Poster session 01
Resources:
Abstract
666P - Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients
Presenter: Sarah Blagden
Session: Poster session 01
667P - Phase I study to assess biodistribution of CB307, a trispecific Humabody targeting CD137, prostate-specific membrane antigen, and human serum albumin with 89Zr-CB307 PET
Presenter: Daan Geert Knapen
Session: Poster session 01
668P - First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable disease
Presenter: Thomas Marron
Session: Poster session 01
669P - CBX-12-101: Final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors
Presenter: Patricia Lorusso
Session: Poster session 01
670P - Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data
Presenter: Martin Wermke
Session: Poster session 01